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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYUsing in vitro and in vivo experimental systems and in situ analysis, we show that growth hormone (GH) is secreted locally by normal
humanmammary epithelial cells upon progesterone stimulation. GH increases proliferation of a subset of cells that express growth hor-
mone receptor (GHR) and have functional properties of stem and early progenitor cells. In 72% of ductal carcinoma in situ lesions, an
expansion of the cell population that expresses GHR was observed, suggesting that GH signaling may contribute to breast cancer devel-
opment.INTRODUCTION
Mammary gland development is controlled by the endo-
crine system, in particular by the ovarian steroid hor-
mones, estrogen and progesterone, and by the pituitary
hormones, growth hormone (GH) and prolactin. Studies
in animal models showed that GH deficiency impairs
mammary gland development. Spontaneous dwarf rats,
which bear a loss-of-function mutation in GH, have defi-
cient alveolar development that can be rescued byGH rein-
fusion (Swanson and Unterman, 2002).Ghr knockout (KO)
mice have retarded duct development and limited side
branching (Bocchinfuso and Korach, 1997; Zhou et al.,
1997). In humans, mutations affecting the expression
and function of the GH receptor (GHR) are collectively
known as Laron syndrome (LS). Similar to Ghr KO mice,
these patients have short stature and reduced body weight
(Laron andKlinger, 1994).Mammary gland development is
affected but can support normal lactation.
Sustained exposure to steroid hormones constitutes one
of the best established factors of risk for breast cancer
(Russo and Russo, 2006). There is compelling evidence,
from both animal work and epidemiological studies, that
elevated levels of GH also increase the risk of breast cancer
(De Stavola et al., 2004; Gunnell et al., 2001). The incidence
of cancers is higher in patients with acromegaly, a condi-
tion associated with hypersecretion of GH (Jenkins, 2004;
Perry et al., 2008; vanGarderen and Schalken, 2002;Waters
and Barclay, 2007), and in individuals with taller height
(Ahlgren et al., 2004; Green et al., 2011; De Stavola et al.,
2004; Gunnell et al., 2001). Conversely, no cancers have780 Stem Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authorbeen diagnosed so far in patients with LS (two cohorts stud-
ied, of 169 and 230 patients), although they have a higher
longevity than the general population (Laron, 2008). Their
blood relatives had an incidence of cancers of 24%.
There is evidence that GH can be secreted by breast
cancer cells (Chiesa et al., 2011; Raccurt et al., 2002).
Studies from Lobie’s group have reported that autocrine
GH signaling in MCF7 cells confers a mesenchymal, inva-
sive phenotype in vitro and generates more aggressive
tumors in vivo (Mukhina et al., 2004). Although the mole-
cular mechanisms underlying steroid hormones and GH
signaling have been elucidated in studies spanning decades
of research, it is still poorly understood how exposure to
these hormones increases risk of breast cancer.
In this study, we utilized a combination of in vitro and
in vivo functional assays and in situ analysis of normal
breast epithelium to show that GH selectively exerts its
effects on normal mammary stem/progenitor cells. We
demonstrated that GHR is expressed in a distinct subpopu-
lation of cells with phenotypic and functional properties of
stem and early progenitor cells. We also showed that a
subpopulation of breast epithelial cells produces GH
upon progestin stimulation. GH/GHR signaling increases
proliferation of mammary stem and progenitor cells. We
speculate that sustained GH stimulation, linked to sus-
tained progesterone stimulation, can increase the risk of
malignant transformation by expanding the stem/progen-
itor cell population and increasing their proliferation rate.
Consistent with this concept, we found that 90% of ductal
carcinoma in situ (DCIS) lesions have a GHR+ cell popula-
tion detectable by immunohistochemistry (IHC). In 72%s
Figure 1. GHR Is Expressed in the Human Mammary Gland Epithelium
(A–C) Immunostaining of normal breast epithelium shows that GHR is expressed mostly in clusters and rarely as scattered cells. Repre-
sentative images of eight samples.
(D–F) Double IF of normal breast epithelium shows that GHR is expressed mostly in ALDH1A1+ cells or in their immediate proximity.
(G and H) Single IF for GHR and ALDH1A1 in consecutive normal breast sections.
(I) Detail of (E), showing ALDH1A1+/GHR+ cells.
(J–L) Double IF for ALDH1A3 and GHR shows isolated GHR+ cells adjacent to ALDH1A3+ cells (arrowheads). Representative images of five
samples.
(M) Flow cytometry for GHR and CD10 showing no overlap between cells expressing these markers. Representative data from two different
samples.
(N) Flow cytometry for GHR and CK18 showing a small overlap (4%) between these markers. Representative data from two different samples.
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to normal tissue. We also showed that inhibition of GH
signaling halts the growth of a patient-derived breast
cancer xenografted in immunodeficient mice.RESULTS
GHR Is Present in a Subset of Normal Human Breast
Epithelium Cells that Express Stem Cell Markers and
Lack Lineage Differentiation Markers
GHR Is Expressed in the Normal Human Mammary Epithelium
We performed immunofluorescent (IF) staining for GHR
on normal human breast sections (aesthetic mammo-Steplasty samples). GHR was detected in all samples
analyzed, originating from eight patients. The vast major-
ity of GHR+ cells in the epithelium were present in cell
clusters, and a small minority were present as scattered,
isolated cells (Figures 1A–1C). GHR+ cells were present
in 1.2%–5% of mammary epithelial cells (four patients,
three paraffin blocks/ sample, 4,359 ± 2,555 average num-
ber cells analyzed/sample). We utilized flow cytometry
analysis for a more sensitive and quantitative assessment
and found that GHR was expressed in 3.5%–19% of
normal breast epithelial cells (mean = 9.7 ± 6.27 SD, n =
6) (staining controls are shown in Figures S1A–S1F avail-
able online).m Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authors 781
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In previous global profiling studies, we found that GHR
transcript was 6-fold upregulated in progenitor versus
more differentiated cells in normal breast epithelium
(Dontu et al., 2003). We enquired now if GHR protein
was present in breast stem/progenitor cells. Two distinct
sets ofmarkers were found to be associatedwith the highest
proliferation potential and the broadest differentiation
potential of breast cells in vitro and in vivo: aldehyde dehy-
drogenase (ALDH) activity, as determined by the
ALDEFLUOR assay, and CD49high/EpCAM/lineage
cells, as determined by flow cytometry (Ginestier et al.,
2007; Lim et al., 2009). We identified the equivalent of
these cell populations in situ, by IF staining for ALDH1A1
and ALDH1A3 and double IF staining for CD49f and
EpCAM. The combination of ALDH1A1 and ALDH1A3 iso-
forms identifies normal breast epithelial cells with ALDH
activity (Honeth et al., 2014). ALDH1A1+ and ALDH1A3+
cells were present primarily as rare clusters of cells and
infrequently as scattered, isolated cells (Figures 1D–1L; Fig-
ures S2A–S2H). Double IF staining showed that GHR was
expressed mainly in ALDH1A1+ cells or in their immediate
proximity (75% of GHR+ cell clusters overlapped with
ALDH1A1+ areas) (Figures 1D–1I; Figures S2A–S2F). Single
staining of consecutive sections confirmed these conclu-
sions (Figures 1G and 1H; Figures S2E and S2F). GHR+ cells
were also found adjacent to ALDH1A3+ areas (Figures 1J–
1L; Figures S2G and S2H). More than half of GHR+ cells
(56%) present as isolated cells or small cell clusters were
adjacent to ALDH1A3+ cells. Given the small size of these
cell populations (all less than 10% average), the probability
of this overlap/juxtaposition to be random is low (p <
0.0001, Fisher’s exact test). For quantitative assessment,
we used ALDEFLUOR and fluorescence-activated cell sort-
ing (FACS) to separate ALDH+ and ALDH cells from
normal breast epithelium. Subsequent GHR staining and
analysis of sorted cells showed that approximately two-
thirds of the ALDH+ cells were GHR+ (mean 59.3 ± 7.0
SD, n = 3) (Figure S2I). GHR+ cells were also found adjacent
and/or overlapping with CD49f+/EpCAM cells (stem/
progenitor cells), as well as with CD49f+/EpCAM+ cells
(luminal progenitor cells) (Figures S2J–S2Q) (Lim et al.,
2009). Flow cytometry using CD49f, EpCAM, and GHR
showed the presence of CD49f+EpCAM-GHR+ and
EpCAM+GHR+ cells, consistent with the results of in situ
analysis (Figures S2R–S2T).
GHR+ Cells Do Not Express Markers of Lineage Differentiation
In order to determine if GHR+ cells associate with a spe-
cific cell lineage, we performed double IF staining for
GHR and CD10 or cytokeratin 18 (CK18) on single cell
suspension from dissociated mammoplasty tissue. CD10
and CK18 are present in the vast majority of myoepithe-
lial and luminal cells, respectively, that form the two782 Stem Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authormain layers of the mammary tree duct. Flow cytometry
analysis did not detect CD10+ cells within the GHR+
cell population (Figure 1M). A subpopulation of CK18+
cells was detected in the GHR+ cell population (approxi-
mately 0.4% of the total epithelial population) (Fig-
ure 1N). Analysis of sections immunostained for GHR
and lineage markers showed similar results. The majority
of the GHR-expressing cells did not express EpCAM,
CK18, CD10, or smooth muscle actin (SMA). This latter
marker is associated with myoepithelial cells. We found
only very rare, isolated GHR+ cells expressing EpCAM,
CK18, or CD10. We did not find any SMA+ cells that
expressed GHR (Figures S3A–S3F). We detected GHR
colocalizing with CK14 and CK5 in cells of the intra-
lobular epithelium, but not those of larger ducts (Figures
S3G–S3J). These cytokeratins are associated with progeni-
tor cells (Villadsen et al., 2007).
GHR+ Cells Have Functional Properties of Stem/
Progenitor Cells
GHR+ Cells from the Normal Breast Epithelium Can Form
Mammospheres
In order to assess the functional potential of GHR+ cells, we
separated GHR+ and GHR normal human mammary
epithelial cells (HMECs) from mammoplasty tissue by
FACS and assessed their ability to form mammospheres
(Figures 2A and 2B). Several groups have demonstrated
that mammosphere-initiating cells from both mouse and
human mammary gland have the highest ability to repo-
pulate the cleared mammary fat pad in vivo (as low as ten
cells generate outgrowths [Cicalese et al., 2009; Pece
et al., 2010]). We found that only GHR+ cells generated
mammospheres, whereas GHR cells failed to do so (Fig-
ure 2B). The efficiency of mammosphere formation was
constant over three passages in vitro (data not shown).
GHR+ Mammary Epithelial Cells Can Differentiate along
Luminal and Myoepithelial Lineages
In order to assess the differentiation potential of GHR+ and
GHR cells, FACS-separated cells were plated at clonogenic
densities, in differentiating conditions. Colonies were
assessed for expression of lineage differentiation markers,
SMA and CK18. There was a higher representation of
progenitor cells with bipotent and myoepithelial differen-
tiation potential in the GHR+ cell population compared
to the GHR cell population (Figure 2C). The sorted
CD49f+EpCAM+GHR+ cells generated predominantly
luminal colonies (90%) and CD49f-EpCAM+GHR+ cells
generated mixed, luminal, and myoepithelial colonies
(data not shown). Additionally, we plated GHR+ and
GHR sorted cells onto a collagen substratum and
analyzed the expression of lineage markers in the entire
population of progeny cells, after 10 days in culture. As
shown in Figure 2D, GHR+ cells generated single positives
Figure 2. Functional Potential of GHR+ Cells In Vitro and In Vivo
(A) Primary HMECs were stained for GHR and then separated by FACS into GHR+ and GHR cells.
(B) GHR+ cells generated mammospheres in suspension culture, whereas GHR cells did not (five independent experiments on different
patient samples, each performed in triplicate, n = 5).
(C) Colony-forming ability of sorted GHR+ and GHR populations. The GHR+ population gave rise to more colonies with mixed phenotype
and less pure luminal colonies compared to the GHR population (representative example from three independent experiments, on two
different patient samples, each performed in triplicate, n = 3).
(D–I) Lineage differentiation potential of the progeny derived from GHR+ (D–E) and GHR cells (H–I), analyzed by flow cytometry.
Progeny of GHR+ cells comprised of myoepithelial cells (CD10+) (D), luminal cells (EpCAM+), and EpCAM/CD10 cells (E). GHR+ cells
generated both GHR+ (red circle) and GHR (blue circle) cells. Progeny of GHR cells were predominantly EpCAM+ and CD10 (H), and
they were comprised of only GHR cells (I). (F–G) After 10 days in culture the progeny of GHR+ cells was sorted in GHR+ and GHR cells
and analyzed by flow cytometry. The GHR+ population comprised myoepithelial cells (CD10+) and EpCAM/CD10 cells (F). A majority of
GHR cells expressed the luminal marker EpCAM (G) (three independent experiments on different patients samples, n = 3).
(J) Ability of GHR+, GHR, or unseparated cells (sorted on viability alone) to generate outgrowths in vivo in humanized fat pads of NOD/
SCID mice.
(K–L) Representative images of outgrowths generated in vivo by unseparated breast epithelial cells.
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double-negative cells, for these markers. This cell progeny
included both GHR+ and GHR cells (Figure 2E). Analysis
of resorted cell populations showed that theGHR+ progeny
was EpCAM-CD10+ or EpCAM-CD10 (Figure 2F),
whereas the majority of GHR progeny were
EpCAM+CD10 (Figure 2G). GHR cells generated pre-
dominantly luminal EpCAM+/CD10 cells and only
GHR progeny (Figures 2H and 2I). Collectively, theseStedata show that GHR+ cells have a broader differentiation
potential compared to GHR cells.
Potential of GHR+ Cells to Generate Outgrowths In Vivo
To test the functional potential of GHR+ cells in vivo, we
separated GHR+ and GHR cells by FACS. Cells sorted on
viability alone (unseparated cells) were used as controls.
We implanted cells from these three subpopulations into
the humanized cleared mammary fat pads of NOD/scid
mice, as previously described (Ginestier et al., 2007;m Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authors 783
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in the fat pads implanted with unseparated cells (Figures
2J–2L). These results, consistent in five mammoplasty
samples, suggest that paracrine or juxtacrine signaling
between GHR+ and GHR cell populations may be impor-
tant for proliferation of xenotransplanted cells. This
conclusion was supported by experiments in which
GHR+ and GHR separated cells were mixed and im-
planted together in the fat pad (total of 50,000 cells/fat
pad), which resulted in outgrowths in all implantations.
Paracrine communication between GHR+ and GHR cells
are likely to involve additional signals beside GH, because
treatment with GH antagonist or knockdown (kd) of
GHR did not affect proliferation of mammary cells in sus-
pension culture (data shown below). Moreover, although
Ghr KO in vivo impairs mammary gland development, it
does not abolish it (Laron and Klinger, 1994; Zhou et al.,
1997). Alternatively, these results may reflect conditions
specific to xenotransplantation that do not entirely recapit-
ulate the physiological human breast environment.
GH/GHR Activation Increases Proliferation of
Mammary/Stem Progenitor Cells
GH Treatment Increases Mammosphere Formation
To determine the functional significance of GHR expres-
sion in normal mammary stem/progenitor cells, we
assessed the effect of GH treatment on mammosphere
formation. Human recombinant GH was used at doses of
3 ng, 10 ng, 30 ng, 100 ng, and 1 mg/ml, corresponding
to physiological serum levels of GH in adulthood, in child-
hood, and in pathologic conditions, such as acromegaly
and pituitary tumors, respectively (Corneli et al., 2007).
GH dose was optimized in MCF10A cells. Increased levels
of phosphorylated Stat5, a known downstream target of
GHR, were observed upon treatment with doses of GH
that increased mammosphere formation (Figure S4A).
MCF10A cells are normal-like mammary epithelial cells
that express both GHR and GH (Figures S4B and S4C).
The effect of GH and GHA treatment on proliferation of
MCF10A cells as spheres was similar to that seen in normal
mammary epithelial cells (Figure S4D).
In HMEC cultures, we observed a dose-dependent in-
crease in mammosphere formation upon treatment with
GH. Concomitant treatment with GH antagonist (GHA)
abolished this effect (Figure 3A). Increased sphere forma-
tion was maintained in secondary and tertiary passages,
when GH treatment was applied in primary culture only
(10 ng/ml) (Figure 3B). The cell composition of these
spheres was similar in all passages, indicating that GH
treatment did not favor differentiation along a particular
lineage (Figure 3C). Because GH can also activate the pro-
lactin receptor, we investigated if the effect on mammo-
sphere formation was dependent on GHR. To this end,784 Stem Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authorwe knocked down GHR in HMECs. GHR kd cells formed
spheres with similar frequency as control cells but failed
to respond to GH stimulation. GH treatment increased
sphere formation in cells infected with nonsilencing small
hairpin RNA (shRNA) (Figures 3D and S4E). Analysis of
PKH26 dye retention, performed on mammosphere-
derived cells, indicated that treatment with GH did not
change the ratios of the PKH26 high, medium, and low
cells, which correspond to stem, early progenitor, and
late progenitor cells (Pece et al., 2010) (Figure S4F).
The effect on sphere formation suggested that GH may
stimulate stem/progenitors to enter the cell cycle. Indeed,
western blot (WB) analysis showed a decreased level of
p21 (amarker associated with quiescence) and an increased
level of MCM2 (a marker associated with dividing cells) in
mammosphere-derived cells treated with GH compared to
control (Figure 3E).
GH Treatment Increases Clonogenicity of Normal Mammary
Epithelial Cells in Adherent Culture
We assessed the effect of GH treatment (10 ng/ml) on
proliferation of HMECs in adherent conditions, at high-
or low- (clonogenic) density plating. GH treatment
increased clonogenicity 2-fold, an effect similar to that
seen in suspension culture (Figure 3F). The increase in
proliferation in high-density culture was more modest
but statistically significant (Figures 3G and S4G). These
findings support the conclusion that GH treatment in-
creases the number of cycling stem/progenitor cells, but
not that of more differentiated progenitors, that represent
the majority of proliferating cells in adherent culture.
This is consistent with the higher representation of GHR+
progenitor cells in mammospheres, compared to adherent
culture (Figures S4D–S4G).
Progestins Induce GH Secretion by Normal Human
Mammary Epithelium
Experiments in female dogs showed that GH is secreted in
the normal mammary epithelium in vivo, upon treatment
with progestins (Selman et al., 1994). We found that GH
was also present in a subset of human mammary epithelial
cells (Figures 4A and 4B). Double staining for GH and
ALDH1A1 showed thatGH is expressed inALDH1A1+ areas
or in their immediate proximity (Figures 4C, S5A, and S5B).
The majority of cells secreting GH were not ALDH1A1+
however. A subpopulation of HMECs stained positive for
GH in primary culture as well (Figure 4D).
To test if progestins stimulate GH production, as is the
case in dogs, we treated human mammosphere cultures
with progesterone (P4) and medroxyprogesterone acetate
(MPA), alone or in combination, and performed qRT-PCR
and WB analysis for GH. (Henceforth ‘‘progestins’’ refers
to synthetic compounds P4 and MPA, and progesterone
refers to endogenous hormone.) We found a significants
Figure 3. GH/GHR Signaling Is Active in Mammary Progenitor Cells
(A) A dose-dependent increase in mammosphere formation was observed upon treatment of primary HMECs with human recombinant GH.
GHA abolished this effect, but did not have an effect when used alone (five independent experiments in different patient samples, each
performed in triplicate, n = 5).
(B) Increased sphere formation was maintained in subsequent passages, although treatment (GH 10 ng/ml, GHA 100 ng/ml, GH+GHA) was
applied only in primary culture (representative example from three independent experiments on different patient samples, each performed
in triplicate, n = 3).
(C) GH treatment did not change the differentiation potential of cells composing the mammospheres. Primary, secondary, and tertiary
mammospheres were dissociated, and single cells suspensions were plated at clonogenic densities on a collagen substratum in the
presence of serum. After 12 days, colonies were immunostained with lineage markers (EpCAM and CD10 or CK18 and CK14). Colonies were
scored based on cell composition, and percentages are shown for GH-treated and control samples (p > 0.05 for all three passages and types
of colonies) (three independent experiments on two patient samples, each performed in triplicate, n = 3).
(D) Knockdown (kd) of GHR in primary HMECs did not affect sphere formation. In GHR kd cell cultures, mammosphere formation was not
changed by GH treatment (representative example from four independent experiments on three patient samples, each performed in
triplicate, n = 3).
(E) WB analysis showed increased level of proliferation marker MCM2 and decreased level of quiescence marker p21 after GH treatment
(10 ng/ml).
(F) GH treatment (10 ng/ml) increased more than 2-fold clonogenicity of primary HMECs in adherent culture (representative example from
four independent experiments on different patient samples, each performed in triplicate, n = 3).
(G) Proliferation of primary HMECs grown in adherent conditions was increased in GH-treated cultures compared to control (representative
example from three independent experiments, on different patient samples, each performed in triplicate, n = 3).
Data are presented as means ± SD.
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treated with P4 or P4+estrogen (E2) (Figures 4E–4K). Doses
of progestin treatmentwere optimized in T47D cells, which
express high levels of PR (Figures 4G and S5C). Treatment
with PR antagonist RU468 abolished these effects, evenStein combined treatment E2+P4 (Figures 4F and 4I). E2 alone
did not have a significant effect (Figures 4E and 4K). Treat-
ment with estrogen receptor alpha (ER) antagonist ICI
182.780 (ICI) decreased the effect of E2+P4 treatment,
probably by decreasing the number of PR+ cells, capablem Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authors 785
Figure 4. GH Is Secreted by Human Normal Mammary Epithelium, upon P4 or MPA Treatment Alone or in Combination with E2
(A–D) GH is secreted by primary HMECs in vivo and in vitro, as shown by immunostaining for GH in situ, in normal breast sections (A and B).
Double staining for GH and ALDH1A1 on normal breast sections shows that GH is present in cells adjacent to ALDH1A1+ cells (C). GH is
detected in vitro in HMECs grown in primary culture on a collagen substratum (D).
(E and F) Treatment with E2+P4 increases levels of GH mRNA in mammary epithelial cells grown as mammospheres (E) or on collagen
substratum (F). Cells were treated with a combination of E2+P4, a combination of E2+P4+ICI182.780 (ER antagonist) or with E2 alone for
24 hr (representative example from four independent experiments on different patient samples, each performed in triplicate, n = 3) (E).
Cells were treated with a combination of E2+P4 for 1 and 4 hr, in presence or absence of PR antagonist RU486 (representative example from
three independent experiments on different patient samples, each performed in triplicate, n = 3) (F).
(G) WB analysis of GH protein levels in T47D cells treated with MPA (0, 1, 10, and 20 nM) for 6 hr was performed to assess dose effect.
Treatment did not change PR protein levels.
(H–K) WB analysis of GH protein level in primary mammospheres treated with E2+P4 (H), E2+ MPA (I), or P4 alone (J). PR antagonist RU486
abolished the increase in GH level induced by P4 (I). Treatment with E2 alone did not increase GH level (K) (representative WB from
experiments using four different mammoplasty samples are shown). Densitometry using ImageJ was performed for quantification. In-
tensity of bands was normalized against loading controls. Ratios between treated versus control samples are shown. Difference between GH
levels in control cells and cells treated with P4 was statistically significant (p < 0.05), as well as cells treated with E2 and P4 (p < 0.005,
two-way ANOVA).
(L–P) Double immunostaining for GH and PR on normal mammary epithelium shows rare PR+ cells secreting GH (M–P, arrowheads).
(Q) IHC for PR and GH on mammosphere sections.
Data are presented as means ± SD.
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tained for treatment with MPA or P4+MPA (data not
shown). In the mammary tissue of dogs, GH was detected
in PR+ cells (Lantinga-van Leeuwen et al., 2000). Double
IF for PR and GH in sections of normal breast epithelium786 Stem Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authorshowed rare GH+PR+ cells; the majority of GH+ cells were
adjacent to PR+ cells (Figures 4L–4P). Similar results were
observed in primary HMECs in adherent culture (Figures
S5D and S5E) and in suspension culture (Figures 4Q, S5F,
and S5G).s
Figure 5. GH Is One of the Paracrine Signals that Increases Mammosphere Formation following Treatment with P4
(A–C) Double immunostaining for GHR with PR (A and B) or ER (C) on normal mammary epithelium shows no colocalization of GHR with
either of these markers.
(D) Mammosphere formation was increased by treatment with conditioned medium (CM) from previous culture treated with MPA, P4, or
E2+MPA, compared to control (CM from nontreated culture, NT). The increased mammosphere formation was inhibited by PR antagonist
RU486 or by GHA. No effect was observed when conditioned medium from E2 alone was used (three independent experiments on different
patient samples, each performed in triplicate, n = 3).
(E) Mammosphere formation was increased by treatment with conditioned medium (CM) from previous culture treated with P4 or E2+P4,
compared to control (CM(NT)). The increase in mammosphere formation was inhibited by GHA (representative example form three in-
dependent experiments on different patient samples, each performed in triplicate, n = 3)
(F) Mammosphere formation was increased upon treatment with conditioned medium from P4-treated cultures CM (P4) in cultures of
primary mammary epithelial cells infected with nonsilencing shRNA, but not in cultures of GHR kd cells (representative example from three
independent experiments in different mammoplasty samples, each performed in triplicates, n = 3).
Data are presented as means ± SD.
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Progesterone and Acting on Mammary Stem/
Progenitor Cells
There is evidence that human normal mammary stem cells
do not express ER and PR (Honeth et al., 2014; Lim et al.,
2009). Double IF staining of normal breast sections showed
that GHR+ cells were ER and PR (Figures 5A–5C). As GH
can be secreted in response to progestins and acts on GHR+
cells, we hypothesized that GH/GHR activation is part of
the paracrine communication that conveys proliferation
signals initiated by steroid hormones to ER/PR mam-
mary stem/progenitor cells.
To test this hypothesis, we utilized mammosphere
cultures, which enrich in GHR-expressing stem/progeni-
tor cells. Conditioned medium (CM) from mammosphere
culture treated with progestins or progestins+E2 signifi-
cantly increased mammosphere formation in new culture.
The effect was specific to progestins because it was abol-
ished by the PR antagonist RU468 (Figure 5D). GHA treat-Stement significantly decreased sphere formation in these
cultures (Figures 5D and 5E). The effect was dependent
on GHR, because kd of GHR rendered mammary epithelial
cells nonresponsive to stimulation with CM from P4-
treated cultures (Figure 5F). Collectively, these data indi-
cate that in the human mammary gland, GH secretion
and GH/GHR activation are linked to steroid hormone
stimulation. A role of GH in mediating paracrine effects
initiated by progesterone and conveyed to an ER/PR
stem/progenitor cell population is also consistent with
the results of in vivo experiments shown above, in which
HMECs separated based on GHR expression loose ability
to generate outgrowths upon xenotransplantation in
NOD/scid mice.
GHR Defines a Cell Population that Is Expanded in
DCIS Lesions
Our findings suggested that a higher rate of proliferation
in the stem/progenitor cell compartment, induced bym Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authors 787
Figure 6. GHR Defines a Cell Population that Is Expanded in DCIS
(A and B) Representative images of GHR immunostaining of DCIS cores on TMAs. Examples of DCIS areas showing no expanded GHR+
population (A) or of positive areas with homogeneous high cytonuclear GHR expression (B).
(C–E) Expanded GHR+ cells population were found in DCIS areas (E) adjacent to areas of normal epithelium, with isolated GHR+ cells (D).
(F–N) Immunostaining for GHR, ALDH1A1/ER, and ALDH1A3 on consecutive sections of DCIS samples on TMAs. The same TMA core contains
DCIS areas that are GHR/ALDH1A1/ER/ALDH1A3+ (I–K), as well as areas that are GHR+/ALDH1A1+/ER+/ALDH1A3 (GHR and
ALDH1A1 are present in a minority of cells, brown and red arrows, respectively) (L–N).
(O) Effects of GHR antagonist Pegvisomant on growth of established tumors. Patient-derived breast cancer xenografts, injected in the
mammary fat pad of NOD/Scid mice, were used. Tumor growth was considerably reduced in treated animals compared to control (animals
injected with vehicle alone, n = 5 animals per group).
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tween GH exposure and increased cancer risk. We hypoth-
esized that an expanded GHR+ cell population may be
associated with early stages of malignant transformation.
DCIS is a recognized, although nonobligate, precursor of
invasive breast cancer. We analyzed tissue microarrays
(TMAs) from a series of 175 pure DCIS (no associated inva-
sive carcinoma) samples from Guy’s and St. Thomas’s
Breast Tissue and Data Bank. These patients presented be-
tween 1976 and 2004, with either symptomatic or screen-
detected DCIS. In this cohort, 58% of the DCIS were of
high cytonuclear grade; 34% were of intermediate grade;
and 7% were of low grade. Twenty-eight percent of788 Stem Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authorwomen were 50 years of age or less, and 74% of DCIS
cases were ER+ (Allred score of three or more). Tumors
were considered positive for GHR, where more than
10% cancer epithelial cells stained positive. We found
that 90% of DCIS lesions had GHR+ cells ranging from
10% to 100% of the cell population, with 72% of cases
having more than 20% GHR+ cells (the maximum seen
in normal breast tissue by flow cytometry or IHC). Almost
half of the lesions (47%) hadR50% GHR+ cells (Figure 6).
The intensity of immunostaining varied. A granular
pattern, previously described for GHR staining and
observed by us in normal tissue, was associated with
both cytoplasmic and membrane localizations (Mertanis
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Hormonal Regulation of Breast Stem Cellset al., 1998). In addition, a more uniform cytoplasmic
staining was observed in DCIS lesions (Figure 6). These
data support the concept that an expansion of the
GHR+ progenitor cell population is an early event associ-
ated with malignant transformation.
In order to assess if a correlation between GHR expres-
sion and ALDH1A1 and/or ALDH1A3 is present in DCIS,
as was the case in the normal tissue, we immunostained
consecutive sections of the same TMAs for these markers.
Samples were compared with respect to GHR and
ALDH1A1 expression (75 patients) and GHR and
ALDH1A3 expression (67 patients). ALDH1A1 and ER
double IHC also allowed us to investigate correlation
with ER. Among the analyzed samples, 24 (32%) were
positive for ALDH1A1 (threshold 0) and 16 (24%) for
ALDH1A3 (moderate or strong staining present). These
criteria were established by the pathologist (SP). GHR-
positive samples showed positive correlation with ER
expression (more than 10% cells positive), by Fisher’s
two-sided analysis (p = 0.02). Of the 24 samples that
had detectable ALDH1A1+ cells, 19 were also positive
for GHR, and of the 16 DCIS samples with moderate or
strong ALDH1A3 staining, 11 were positive for GHR.
There was no statistically significant correlation between
GHR expression and either ALDH1A1 or ALDH1A3,
possibly due to the high percentage of GHR-positive
DCIS lesions and the relatively small number of samples
available for comparison. ALDH1A1+ cells appeared to
be overlapping or juxtaposed with GHR in both normal
areas adjacent to the DCIS lesions and within the DCIS
lesions (Figures 6F–6N; Figure S5). GHR+ cells appeared
to be ER+ in the majority of cases, but not always. This
latter observation, and the positive correlation of GHR
and ER across patient samples, supports the hypothesis
that autocrine and paracrine signaling involving GH
and steroid hormones may be involved in breast cancer
initiation and/or progression.
Inhibition of GH Signaling Significantly Reduces Breast Tumor
Growth
It has been shown that growth of tumors generated by sub-
cutaneously injecting the ER-positive breast cancer cell line
MCF7 in immunodeficientmice is considerably reduced by
treatment with the GHA Pegvisomant, a drug used in
patients with acromegaly (Divisova et al., 2006). We inves-
tigated the effect of GHA treatment in an orthotopic xeno-
graft model established from a patient-derived sample.
Tumors were allowed to reach 4mm in the largest diameter
before treatment was initiated. Control animals were
treated with vehicle alone. As shown in Figure 6O, tumor
growth was considerably diminished in treated animals.
This xenograft was established from a triple-negative breast
cancer; therefore, inhibition of GHmay be effective in this
subtype of breast cancers as well.SteDISCUSSION
Initially, the role of GH in both normal breast development
and tumorigenesis was linked to that of prolactin, because
human GH activates both GHR and prolactin receptor.
Subsequently, its role in insulin growth factor-1 (IGF-1)
synthesis by the liver and the importance of the GH/
IGF-1 axis in cancer initiation and progression were
brought to the foreground (Kleinberg et al., 2009; Laban
et al., 2003). More recently, a novel hypothesis was pro-
posed, that autocrine/paracrine mechanisms employing
locally secretedGHmaypromote growth in certain tumors,
independent of IGF-1 signaling (Mukhina et al., 2004; Zhu
et al., 2005). It has been also speculated that the association
between GH and cancer risk is due to an effect on the stem/
progenitor cell population (Green et al., 2011).
In this studywe explored this latter hypothesis and inves-
tigated the effect of GH/GHR signaling on a subpopulation
of mammary cells with functional properties of stem/pro-
genitor cells. We detected GHR in normal breast epithelium
in distinct clusters of cells, either overlapping with or
in proximity of stem/progenitor cells (ALDH1A1+ or
CD49f+/EpCAM cells) or luminal progenitor cells
(ALDH1A3+ or CD49f+/EpCAM+ cells). GHR+ cells did not
expressmarkers of lineagedifferentiation, ER, or PR. In func-
tional assays, GHR+ cells displayed properties of stem and
progenitor cells, being capable of initiating mammosphere
formation and generating both luminal and myoepithelial
lineage. GHR+ and GHR cells did not proliferate in vivo
when separated but were capable of generating outgrowths
when recombined. These results suggest the existence of
paracrine or juxtacrine communication between GHR+
and GHR cells, necessary for proliferation in the mouse
environment. Treatment of normal breast epithelial cells
with recombinant GH in adherent and nonadherent pri-
mary cultures increased clonogenicity, an effect abolished
by GHA inhibitor or by GHR kd. Upregulation of the prolif-
erationmarkerMCM2 and downregulation of the cell-cycle
inhibitor p21 accompanied these effects.
We also showed that GH can be secreted locally in the
mammary gland, by a population of cells situated in prox-
imity of PR+ cells. Treatment with progestins increased GH
mRNA and protein levels in normal breast epithelial cells.
Indirect evidence for a link between GH secretion and
progesterone also comes from studies in human patients
in which serum peaks of GH correlate with those of proges-
terone in 24 hr cycles or during the lutheal phase of the
menstrual cycle (Caufriez et al., 2009, 2011).
Signaling through ER and PR is critical for mammary
morphogenesis (Bocchinfuso and Korach, 1997; Sternlicht,
2006). Mouse mammary stem cells do not express ER or PR
but respond to progesterone stimulation through indirect
mechanisms, involving RANK-L, amphiregulin, and Wntm Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authors 789
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2000; Joshi et al., 2010). There is evidence that human
mammary stem/progenitor cells are ER/PR as well (Hon-
eth et al., 2014; Lim et al., 2009). ALDH1A1+ cells and
mammosphere-initiating cells of human origin, are also
ER, but can generate ER+/PR+ cells (Honeth et al.,
2014). We showed here that treatment with progestins
increased mammosphere formation through paracrine
mechanisms mediated by GH. GHA treatment and GHR
kd abolished this effect. We propose that part of the
communication between PR+ mammary epithelial cells
and GHR+ progenitor cells is mediated by GH.
We speculate that in vivo, serum GH of pituitary and
placental origin may be responsible for the expansion of
mammary stem/progenitor cells during developmental
windows when the mammary gland grows isometrically
(intrauterine life, childhood). In adulthood, when GH
secretion from the pituitary gland decreases, this hormone
is secreted locally in the mammary gland, in response to
progesterone stimulation. This process may contribute to
additional expansion of the stem/progenitor cell popula-
tions during the lutheal phase of the menstrual cycle and
during pregnancy, when the mammary gland does not
grow isometrically. In a process reminiscent of ‘‘niche for-
mation,’’ ER stem/progenitor cells generate sensory ER+
cells (Honeth et al., 2014). A paracrine signaling loop is
initiated when estrogen peaks at the end of follicular phase
and upregulates PR. Subsequently, progesterone peaks in
the lutheal phase and activates PR molecular targets. We
propose that GH is secreted as long as progesterone levels
are high. Mitogenic signals are conveyed by GH to neigh-
boring GHR+ stem/progenitor cells (Figures 7A and 7B). If
these cycling progenitor cells divide further and generate
differentiated cells, the ratio between stem/progenitor
and differentiated cells will be maintained relatively con-
stant. Unlike other tissues, however, proliferation of breast
cells follows the cyclic fluctuation of ovarian hormones
(Russo and Russo, 2006). The cumulative effect of pro-
longed exposure to steroid hormones and/or GH during
many menstrual cycles would lead eventually to changed
ratios between progenitor and differentiated cells, in favor
of the former. An expanded undifferentiated cell popula-
tion with a higher rate of proliferation would be at higher
risk for transformation through oncogenic hits (Figure 7C).
Consistent with this model, our analysis of DCIS series
showed the presence of an expanded GHR+ cell population
in a majority of these lesions and a positive correlation
between GHR and ER. Cellular colocalization of these two
receptors in DCIS suggests that, upon malignant transfor-
mation, GHR+ cells may secrete GH and proliferate
through autocrine stimulation.
Animals treated with GH develop hyperproliferative
lesions in the mammary gland and have increased inci-790 Stem Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authordence of spontaneous mammary tumors (To¨rnell et al.,
1992; van Garderen and Schalken, 2002; Waters and Bar-
clay, 2007). Conversely, animals deficient in GH signaling,
such as spontaneous dwarf rats or Ghr KO mice, are resis-
tant to carcinogen-induced cancers, including mammary
cancer (Swanson and Unterman, 2002). Blocking GH
signaling in mice xenografted with the ER-positive breast
cancer cell line MCF7 considerably reduced tumor size
and prolonged latency of tumor formation (Divisova
et al., 2006). In our study, we utilized an xenograft model
based on orthotopic implantation of a triple-negative
breast cancer propagated in vivo only. The tumorigenic
cell population of this tumor is represented by cells with
ALDH activity (Ginestier et al., 2007). In this model, a
significant reduction in tumor growth was observed in an-
imals treated with GHA, compared to controls.
Taken together, these findings indicate that exposure to
elevated levels of GH may represent a cumulative factor of
risk for breast cancer as a consequence of effects of this hor-
mone on the breast stem/progenitor cell population. This
may confer a risk similar to that represented by exposure
to steroid hormones and may have clinical implications
forbreast cancer risk assessment,prevention,and treatment.EXPERIMENTAL PROCEDURES
Dissociation of Normal Breast Epithelium
Normal breast tissue was obtained from patients undergoing
mammoplasty for aesthetic reasons, under protocols approved by
the Institutional Review Board and by Guy’s Research Ethics Com-
mittee, in compliance with the Human Tissue Act. The tissue was
processed as previously described (Ginestier et al., 2007).
Mammosphere Culture
Mammosphere culture and dissociation were performed as previ-
ously described (Dontu et al., 2003), at a density of 20,000 viable
cells/ml in primary culture and 5,000 cells/ml in subsequent
passages. Assessing mammosphere formation in cell fractions
sorted by FACS was performed at 1,000 cells/ml. The medium did
not contain B27 or phenol red.
Adherent Culture
HMECs were placed on collagen-coated plates in Dulbecco’s modi-
fied Eagle’s medium-F12 with 5% serum, insulin (5 mg/ml), hydro-
cortisone (1 mg/ml), EGF (10 ng/ml), cholera toxin (10 ng/ml), and
13 Pen/Strep/Fungizone Mix. All media were phenol red free.
Charcoal-stripped serum was used. All reagents were from GIBCO.
Immunostaining and Flow Cytometry
Cells were stained fresh or after fixation in methanol. Antibodies’
source and working dilutions are shown in Table S1. Cells were
stained 20 min on ice in Hank’s balanced salt solution (HBSS;
GIBCO) 2% FBS, then washed in HBSS 2% FBS, and resuspended
in HBSS 5% FBS. Viability stain was performed using 1 mg/mls
Figure 7. Effect of GH Stimulation on Normal Mammary Stem/Progenitor Cells and Implications for Oncogenic Transformation: A
Model
(A) Normal mammary stem cells undergo asymmetric divisions, which generate a stem cell that goes into quiescence and a proliferating
progenitor that gives rise to differentiated progenies. In the presence of GH, the daughter cell destined to become quiescent divides again,
doubling the final total number of progenies.
(B) GH is part of an intercellular signaling loop triggered by E2, which drives expression of PR, followed by P4/PR signaling and local
production of GH. This signaling loop is active as long as steroid hormones levels are elevated (puberty, middle of the menstrual cycle,
pregnancy) and results in an increased number of stem/progenitor cells entering the cell cycle, through GH/GHR activation.
(C) Increased levels or prolonged exposure steroid hormones and/or GH would lead eventually to an expanded undifferentiated population
at a higher risk for transformation through oncogenic hits.
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Hormonal Regulation of Breast Stem Cellspropidium iodide (PI) (Sigma) for 5 min. The cells were gated on
viability and forward scattered in all experiments.
ALDEFLUOR Assay
The ALDEFLUOR Kit (StemCell Technologies) was used in accor-
dance with the manufacturer’s protocol.
TMAs were constructed from 2 mm cores of 175 DCIS cases, in
compliance with the Guy’s and St. Thomas Research Tissue and
Data Bank procedures and with Guy’s Research Ethics Committee
approval.
IHC
Source and working dilutions of antibodies and antigen retrieval
procedures are shown in Table S1. All primary antibodies wereSteincubated for 1 hr, except GH, which was incubated for 15 hr.
Peroxidase Histostain-Plus Kit (Zymed) and EnVision G2 Double-
stain System (Dako) were used in accordance with the manufac-
turer’s protocols.
Immunostaining on Coverslips
Cells were fixed 10 min in 4% paraformaldehyde, washed twice in
PBS, treated with 0.1% Triton X- 100 for 5 min, and incubated in
blocking buffer (PBS 2% BSA) for 1 hr. Primary and secondary
antibodies were incubated for 1 hr in blocking buffer.
WB Analysis
Total cell extracts were electrophoresed on 10% SDS-PAGE gels.
Antibodies were used at dilutions shown in Table S1, in 5% BSAm Cell Reports j Vol. 2 j 780–793 j June 3, 2014 j ª2014 The Authors 791
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4C for primary antibodies and 1 hr at room temperature for
secondary antibodies. A Super SignalWest Pico Chemiluminescent
Substrate Kit System (Thermo Scientific) was used for signal
detection.
GH, E2 P4, and GHA Treatment
Recombinant human GH and GH blocking antibody (GHA) (R&D
Systems) were used in concentration of 3, 10, 30, 100, and
1,000 ng/ml GH and 30, 100, 300, 1,000, and 10,000 ng/ml GHA
alone or in combination. E2, P4, and MPA (Sigma) were used in
concentration of 107 M; ICI 182.780 and RU486 (SLS) were
used at 108 M. To test GH levels by WB, HMECs were treated
with E2 (107 M) for 6 hr and then P4 or MPA (107 M) for
24 hr. T47D cells were treated with MPA (1, 10, and 20 nM) for
6 hr. Cells were serum starved for 24 hr before treatment. For assess-
ing GH mRNA level, cells were treated for 1 or 4 hr with P4, E2,
E2+P4 with or without ICI 182.780, RU486. CM medium was
used in a 1:3 ratio with fresh medium.
GHR Knockdown
Lentiviral vectors (pGIPZ) expressing two selected shRNAs against
GHR (Applied Biosystems) were used in accordance with the man-
ufacturer’s protocol (see also the Supplemental Experimental
Procedures).
In Vivo Treatment of Xenografts
Animal studies were performed under protocols approved by the
University Committee for Use and Care of Animals, University of
Michigan and the Institutional Committees on Animal Welfare
of the United Kingdom Home Office. A patient-derived breast
tumor xenograft was implanted in the fourth mammary fat pat
of NOD/scid mice. Tumors were allowed to reach 4 mm in the
largest diameter before treatment with GHA Pegvisomant (Pfizer)
was initiated. Treatment was done by subcutaneous injection
40 mg/kg, 1/day for 2 weeks. Control animals were treated with
vehicle alone. Each group had five animals. Tumors weremeasured
with calipers every 2–3 days, and the weight of tumors was calcu-
lated using the following formula: weight = l3 h2/2. Animals were
humanely sacrificedwhen tumors in the control group grew bigger
than 1.2 cm in the largest diameter.
Statistical Analysis
The effect on mammosphere formation was tested for statistical
significance by one-way Anova one tail, unequal variance. The
effect of treatment on tumor growth was assessed by two-way
Anova with Sidak’s multiple comparison tests. The correlation
between markers in normal samples was analyzed using Fisher’s
exact test and the correlation between markers in DCIS by two-
way Anova with Sidak’s multiple comparison tests.
SUPPLEMENTAL INFORMATION
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Procedures, six figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2014.
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